Journal of Neural Transmission

, Volume 119, Issue 7, pp 861–875 | Cite as

CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD

  • Alessandro Stefani
  • Livia Brusa
  • Enrica Olivola
  • Mariangela Pierantozzi
  • Alessandro Martorana
Dementias - Review article


Dementia has become a relevant problem associated with the elderly in our countries. Increased interest in the field has yielded a copious literature, so far mostly centered on Alzheimer’s dementia. Cerebrospinal fluid (CSF) analysis combined with neuropsychology, even in absence of neuroimaging, represents the gold standard to reach a diagnosis when cortical cognitive impairment prevails. In view of this, low levels of CSF amyloid peptides β (Aβ) and high tau/Aβ protein ratio, despite prominent impairment of executive functions or concomitant vascular burden, facilitate the diagnosis of Alzheimer’s disease. Conversely, an early cognitive impairment occurring in patients suffering from Parkinson’s disease (PD) or Lewy body disorders (LBDs), both diagnoses posed on pure clinical grounds, remains quite elusive in term of biomarkers or neuropsychological assessment. Whether PD with dementia (PDD) and dementia with Lewy bodies (DLB) represent further steps along with a continuum of the same progressive degeneration due to Lewy bodies deposition, rather then the association of Lewy bodies and Aβ pathology, remains a challenging issue. Aim of this work is to set a state-of-the-art on the neuropsychological profiles of both or DLB. Then, we will focus on the ongoing controversies about the specificity of the standard CSF biomarkers if applied to extrapyramidal disorders. Our conclusions are that the CSF pattern, in PDD and DLB, can certainly be distinct from that in AD, though mechanisms leading to dementia could be shared among them. It is possible that, by combining imaging tracers, neuropsychologically careful assessment and renewed CSF biomarkers, DLB can be better distinguished in subgroups, depending on the presence or absence of a relevant amyloid burden. However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities.


Parkinson’s disease Dementia Lewi body disorders CSF biomarkers 


  1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392PubMedCrossRefGoogle Scholar
  2. Aarsland D, Kurz M, Beyer M, Bronnik K, Piepenstock Nore S, Ballard C (2008) Early discriminatory diagnosis of dementia with Lewy bodies. Dem Other Cogn Dis. 17:195–205CrossRefGoogle Scholar
  3. Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Kim HM, Leverenz JB, Ginghina C, Armaly J, Edwards KL, Snapinn KW, Stoessl AJ, Zhang J (2012) Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. Neurology 78:55–61PubMedCrossRefGoogle Scholar
  4. Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080–1086PubMedCrossRefGoogle Scholar
  5. Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E (2011) The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry 26:100–105PubMedCrossRefGoogle Scholar
  6. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMedCrossRefGoogle Scholar
  7. Biju G, de la Fuente-Fernández R (2009) Dopaminergic function and progression of Parkinson’s disease: PET findings. Parkinsonism Relat Disord Suppl 4:S38–S40CrossRefGoogle Scholar
  8. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231–245PubMedCrossRefGoogle Scholar
  9. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M (2009) Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 27:458–464PubMedCrossRefGoogle Scholar
  10. Brooks DJ (2009) Imaging amyloid in Parkinson’s disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 2(24 Suppl):S742–S747CrossRefGoogle Scholar
  11. Brusa L, Bassi A, Stefani A, Pierantozzi M, Peppe A, Caramia MD et al (2003) Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 110:373–380PubMedCrossRefGoogle Scholar
  12. Brusa L, Tiraboschi P, Koch G, Peppe A, Pierantozzi M, Ruggieri S et al (2005) Pergolide effect on cognitive functions in early-mild Parkinson’s disease. J Neural Transm 112:231–242PubMedCrossRefGoogle Scholar
  13. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C, Alzheimer’s Disease Neuroimaging Initiative (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 67:1370–1378PubMedCrossRefGoogle Scholar
  14. Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord 24:2203–2210PubMedCrossRefGoogle Scholar
  15. Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134:1493–1505PubMedCrossRefGoogle Scholar
  16. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1127PubMedCrossRefGoogle Scholar
  17. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A (2008) CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. Eur J Neurol 15(11):1252–1255PubMedCrossRefGoogle Scholar
  18. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25:2803–2810PubMedCrossRefGoogle Scholar
  19. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458PubMedCrossRefGoogle Scholar
  20. Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, Saraceni T (1988) Dementia and cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:1498–1502PubMedCrossRefGoogle Scholar
  21. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillàn C (2003) Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60:1218–1222PubMedCrossRefGoogle Scholar
  22. Gomis M, Sobrino T, Ois A, Millán M, Rodríguez-Campello A, Pérez de la Ossa N, Rodríguez-González R, Jiménez-Conde J, Cuadrado-Godia E, Roquer J, Dávalos A (2009) Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 40(10):3197–3201PubMedCrossRefGoogle Scholar
  23. Goos JD, Teunissen CE, Veerhuis R, Verwey NA, Barkhof F, Blankenstein MA, Scheltens P, van der Flier WM (2012) Microbleeds relate to altered amyloid-beta metabolism in Alzheimer’s disease. Neurobiol Aging 33:1011.e1–e9Google Scholar
  24. Grilli M, Lagomarsino F, Zappettini S, Preda S, Mura E, Govoni S, Marchi M (2010) Specific inhibitory effect of amyloid-beta on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. Neuroscience 167(2):482–489PubMedCrossRefGoogle Scholar
  25. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H (2010) Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer’s disease. J Alzheimers Dis 22:971–980PubMedGoogle Scholar
  26. Halliday GM, Song YJ, Harding AJ (2011) Striatal β-amyloid in dementia with Lewy bodies but not Parkinson’s disease. J Neural Transm 118:713–719PubMedCrossRefGoogle Scholar
  27. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234PubMedCrossRefGoogle Scholar
  28. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK (2011) Alzheimer’s disease neuroimaging initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77:1619–1628PubMedCrossRefGoogle Scholar
  29. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844PubMedCrossRefGoogle Scholar
  30. Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, Motomura K, Soejima N, Yamasaki R, Hashimoto T, Tabira T, LaFerla FM, Kira J (2011) Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neuro 69:248–256CrossRefGoogle Scholar
  31. Holmberg B, Johnels B, Blennow K, Rosengren L (2003) Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Mov Disord 18:186–190PubMedCrossRefGoogle Scholar
  32. Jellinger KA (2009) Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 24:114–125PubMedCrossRefGoogle Scholar
  33. Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Möller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GM Jr (2000) Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 54:1498–1504PubMedCrossRefGoogle Scholar
  34. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM (2011) Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and from other parkinsonian syndromes. Neurobiol Dis 41:377–384PubMedCrossRefGoogle Scholar
  35. Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 54:1875–1876PubMedCrossRefGoogle Scholar
  36. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, Dickson DW, Parisi JE, Knopman DS, Smith GE, Ferman TJ, Petersen RC, Jack CR Jr (2011) Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2011 Oct 20Google Scholar
  37. Kar S, Slowikowski SP, Westaway D, Mount HT (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29:427–441PubMedGoogle Scholar
  38. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of alpha-synuclein, beta-amyloid 42 and tau in CSF patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81:608–610PubMedCrossRefGoogle Scholar
  39. Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P (2010) Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 29:491–497PubMedCrossRefGoogle Scholar
  40. Kumar U, Patel SC (2007) Immunohistochemical localization of DA receptor subtypes (D1R-D5R) in Alzheimer’s disease brain. Brain Res 1131:187–196PubMedCrossRefGoogle Scholar
  41. Kurz A, Riemenschneider M, Wallin A (2003) Potential biological markers for cerebrovascular disease. Int Psychogeriatr 15(Suppl 1):89–97PubMedCrossRefGoogle Scholar
  42. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ, Alzheimer’s Neuroimaging Initiative (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75:230–238PubMedCrossRefGoogle Scholar
  43. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, PBT2-201-EURO Study Group (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779–786PubMedCrossRefGoogle Scholar
  44. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ (2011) Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 17:61–64PubMedCrossRefGoogle Scholar
  45. Lewczuk P, Popp J, Lelental N, Kölsch H, Maier W, Kornhuber J, Jessen F (2012) Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer’s disease. J Alzheimers Dis 28:119–125PubMedGoogle Scholar
  46. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D (1992) Markers of DA metabolism in Parkinson’s disease. The Parkinson Study Group. Neurology 42:2111–2117PubMedCrossRefGoogle Scholar
  47. Lunardi G, Galati S, Tropepi D, Moschella V, Brusa L, Pierantozzi M, Stefani A, Rossi S, Fornai F, Fedele E, Stanzione P, Hainsworth AH, Pisani A (2009) Correlation between changes in CSF DA turnover and development of dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 15:383–389PubMedCrossRefGoogle Scholar
  48. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34:107–112PubMedCrossRefGoogle Scholar
  49. Martorana A, Stefani A, Palmieri MG, Esposito Z, Bernardi G, Sancesario G, Pierantozzi M (2008) l-Dopa modulates motor cortex excitability in Alzheimer’s disease patients. J Neural Transm 115:1313–1319PubMedCrossRefGoogle Scholar
  50. Martorana A, Mori F, Esposito Z, Kusayanagi H, Monteleone F, Codecà C, Sancesario G, Bernardi G, Koch G (2009) DA modulates cholinergic cortical excitability in Alzheimer’s disease patients. Neuropsychopharmacology 34:2323–2328PubMedCrossRefGoogle Scholar
  51. Martorana A, Esposito Z, Koch G (2010) Beyond the cholinergic hypothesis: do current drugs work in Alzheimer’s disease? CNS Neurosci Ther 16:235–245PubMedGoogle Scholar
  52. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease inpatients with mild cognitive impairment. JAMA 302:385–393PubMedCrossRefGoogle Scholar
  53. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386–395PubMedCrossRefGoogle Scholar
  54. McKeith I (2007) Dementia with Lewy bodies and Parkinson’s disease with dementia: where two worlds collide. Pract Neurol 7:374–382PubMedCrossRefGoogle Scholar
  55. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  56. Metzler-Baddeley C (2007) A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer’s disease and Parkinson’s disease with dementia. Cortex 43:583–600PubMedCrossRefGoogle Scholar
  57. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B (2005) Tau protein, A β42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19:164–170PubMedCrossRefGoogle Scholar
  58. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S, Wiltfang J, Otto M (2006) Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement Geriatr Cogn Disord 22:200–208PubMedCrossRefGoogle Scholar
  59. Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M (2011) CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer’s disease. J Alzheimers Dis 24:383–391PubMedGoogle Scholar
  60. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J (2010) CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord 25:2682–2685PubMedCrossRefGoogle Scholar
  61. Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D (2011a) CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82:160–164PubMedCrossRefGoogle Scholar
  62. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, Blennow K, Zetterberg H, Aarsland D (2011b) Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer’s disease: clinical and neurochemical correlates. Int J Alzheimers Dis 2011:495025PubMedGoogle Scholar
  63. Mura E, Preda S, Govoni S, Lanni C, Trabace L, Grilli M, Lagomarsino F, Pittaluga A, Marchi M (2010) Specific neuromodulatory actions of amyloid-beta on DA release in rat nucleus accumbens and caudate putamen. J Alzheimers Dis 19:1041–1053PubMedGoogle Scholar
  64. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders—a marker of synapse loss? Neurosci Lett 450:332–335PubMedCrossRefGoogle Scholar
  65. Pappatà S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, Amboni M, Erro R, Vitale C, Caprio MG, Pellecchia MT, Brunetti A, De Michele G, Salvatore M, Barone P (2011) Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 77:1357–1362PubMedCrossRefGoogle Scholar
  66. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D’Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64:850–855PubMedCrossRefGoogle Scholar
  67. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P (2012) Performance of Aβ1-40, Aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29:229–238PubMedGoogle Scholar
  68. Pillon B, Deweer B, Agid Y, Dubois B (1993) Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 50:374–379PubMedCrossRefGoogle Scholar
  69. Přikrylová Vranová H, Mareš J, Nevrlý M, Stejskal D, Zapletalová J, Hluštík P, Kaňovský P (2010) CSF markers of neurodegeneration in Parkinson’s disease. J Neural Transm 117:1177–1181PubMedCrossRefGoogle Scholar
  70. Quigley H, Colloby SJ, O’Brien JT (2011) PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 26:991–999PubMedCrossRefGoogle Scholar
  71. Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM (2010) CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis 22(1):87–95PubMedGoogle Scholar
  72. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM (2011) Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 82:1033–1037PubMedCrossRefGoogle Scholar
  73. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18:691–701PubMedGoogle Scholar
  74. Schneider LS, Kennedy RE, Cutter GR, Alzheimer’s Disease Neuroimaging Initiative (2010) Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 6:367–377PubMedCrossRefGoogle Scholar
  75. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78:47–54PubMedCrossRefGoogle Scholar
  76. Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, Stenset V, Fladby T (2010) Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res 7:10PubMedCrossRefGoogle Scholar
  77. Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK (2011) Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis 25:583–594PubMedGoogle Scholar
  78. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570–580PubMedCrossRefGoogle Scholar
  79. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C (2010) CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055–1061PubMedCrossRefGoogle Scholar
  80. Sjögren M, Minthon L, Davidsson P, Granérus A-K, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K (2000) CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 107:563–579PubMedCrossRefGoogle Scholar
  81. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia. Curr Alzheimer Res 7(5):470–476PubMedCrossRefGoogle Scholar
  82. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, Urbani A, Giordano A, Martorana A, Orlacchio A, Federici G, Bernardi G (2005) AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci 237:83–88PubMedCrossRefGoogle Scholar
  83. Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M (2006) CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 251:124–128PubMedCrossRefGoogle Scholar
  84. Thal DR, Griffin WS, Braak H (2008) Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer’s disease. J Cell Mol Med 12:1848–1862PubMedCrossRefGoogle Scholar
  85. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain 129:729–735PubMedCrossRefGoogle Scholar
  86. Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, Poser S, Otto M, Neumann M (2001) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 56:576PubMedCrossRefGoogle Scholar
  87. Tsuboi Y, Uchikado H, Dickson DW (2007) Neuropathology of Parkinson’s disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 13:221–224CrossRefGoogle Scholar
  88. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM (2009) CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 72:1056–1061PubMedCrossRefGoogle Scholar
  89. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73:287–293PubMedCrossRefGoogle Scholar
  90. Verbeek MM, De Jong D, Kremer HP (2003) Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 40:25–40PubMedCrossRefGoogle Scholar
  91. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70:871–880PubMedCrossRefGoogle Scholar
  92. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frölich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78:379–386PubMedCrossRefGoogle Scholar
  93. Weisman D, McKeith I (2007) Dementia with Lewy bodies. Semin Neurol 27:42–47PubMedCrossRefGoogle Scholar
  94. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798PubMedCrossRefGoogle Scholar
  95. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:2958–2969PubMedCrossRefGoogle Scholar
  96. Wu J, Khan GM, Nichols RA (2007) DA release in prefrontal cortex in response to beta-amyloid activation of alpha7 nicotinic receptors. Brain Res 1182:82–89PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Alessandro Stefani
    • 1
    • 3
  • Livia Brusa
    • 2
  • Enrica Olivola
    • 1
  • Mariangela Pierantozzi
    • 1
    • 3
  • Alessandro Martorana
    • 1
  1. 1.Dipartimento di NeuroscienzeUniversità di Roma “Tor Vergata”RomeItaly
  2. 2.UOC Neurologia, Ospedale Sant’EugenioRomeItaly
  3. 3.IRCCS Santa LuciaRomeItaly

Personalised recommendations